Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 04, 2016. The document serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific share transaction and does not contain financial statements or performance metrics.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific change in shareholding for a connected person of a Person Discharging Managerial Responsibilities.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports a share acquisition event.
Important Facts for Investors
- Transaction Date: May 04, 2016.
- Individual Involved: Dr S Dexter, a Connected Person of Dr P J T Vallance (Person Discharging Managerial Responsibilities).
- Transaction Type: Acquisition of 844 GSK ordinary shares.
- Price: 1510.58 pence per share.
- Context: The acquisition resulted from the re-investment of the dividend paid to shareholders on April 14, 2016.